Development of new levodopa treatment strategies in Parkinson’s disease—from bedside to bench to bedside

References

• Ordenstein L. Sur la paralysie agitante et la sclérose en plaques généralisée. Delahaye. 1868.
   Google Scholar
• Tretiakoff C. Contribution a l’etude de l’anatomie pathologique du locus niger de soemmering avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. Doctoral thesis. Paris. 1919.
   Google Scholar
• Carlsson A, Lindqvist M, Magnusson T, Waldeck B. On the presence of 3-hydroxytyramine in brain. Science. 1958;127:471.
   PubMed Web of Science ®Google Scholar
• Anden NE, Carlsson A, Dahlstroem A, Fuxe K, Hillarp NA, Larsson K. Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci. 1964;3:523–30.
   Web of Science ®Google Scholar
• Ehringer H, Hornykiewicz O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960;38:1236–9.
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Hornykiewicz O. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr. 1961;73:787–8.
   PubMedGoogle Scholar
• Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276:374–9.
   PubMed Web of Science ®Google Scholar
• Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism–chronic treatment with L-dopa. N Engl J Med. 1969;280:337–45.
   PubMed Web of Science ®Google Scholar
• Bartholini G, Constantinidis J, Tissot R, Pletscher A. Formation of monoamines from various amino acids in the brain after inhibition of extracerebral decarboxylase. Biochem Pharmacol. 1971;20:1243–7.
   PubMed Web of Science ®Google Scholar
• Aquilonius SM, Eckernas SA. Cortical and striatal in vivo uptake and metabolism of plasma choline in the rat: effects of haloperidol and apomorphine. Acta Pharmacol Toxicol (Copenh). 1976;39:129–40.
   PubMedGoogle Scholar
• Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol. 1969;21:343–54.
   PubMed Web of Science ®Google Scholar
• Fahn S. ‘On-off’ phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology. 1974;24:431–41.
   PubMed Web of Science ®Google Scholar
• Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 1975;25:1144–8.
   PubMed Web of Science ®Google Scholar
• Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson’s disease: response to intravenous infusion of levodopa. Lancet. 1982;2:412–15.
   PubMed Web of Science ®Google Scholar
• Juncos J, Serrati C, Fabbrini G, Chase TN. Fluctuating levodopa concentrations and Parkinson’s disease. Lancet. 1985;2:440.
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, Part I. Ann Neurol. 1988;24:366–71.
   PubMed Web of Science ®Google Scholar
• Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol. 1986;20:262–5.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Aquilonius SM. Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin Neuropharmacol. 2004;27:245–56.
   PubMed Web of Science ®Google Scholar
• Aquilonius SM, Bergstrom K, Eckernas SA, Hartvig P, Leenders KL, Lundquist H, et al. In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography. Acta Neurol Scand. 1987;76:283–7.
   PubMed Web of Science ®Google Scholar
• Eckernas SA, Aquilonius SM, Hartvig P, Hagglund J, Lundqvist H, Nagren K, et al. Positron emission tomography (PET) in the study of dopamine receptors in the primate brain: evaluation of a kinetic model using 11C-N-methyl-spiperone. Acta Neurol Scand. 1987;75:168–78.
   PubMed Web of Science ®Google Scholar
• Hagglund J, Aquilonius SM, Bergstrom K, Eckernas SA, Hartvig P, Lundqvist H, et al. Regional kinetics of [11C]methylspiperone in the brain studied by positron emission tomography in patients with Parkinson’s disease. Adv Neurol. 1987;45:99–101.
   PubMedGoogle Scholar
• Leenders KL, Aquilonius SM, Bergstrom K, Bjurling P, Crossman AR, Eckernas SA, et al. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res. 1988;445:61–7.
   PubMed Web of Science ®Google Scholar
• Tedroff J, Aquilonius SM, Hartvig P, Lundqvist H, Gee AG, Uhlin J, et al. Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson’s disease. Acta Neurol Scand. 1988;77:192–201.
   PubMed Web of Science ®Google Scholar
• Tedroff J, Aquilonius SM, Laihinen A, Rinne U, Hartvig P, Anderson J, et al. Striatal kinetics of [11C]-(+)-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson’s disease measured with positron emission tomography. Acta Neurol Scand. 1990;81:24–30.
   PubMed Web of Science ®Google Scholar
• Tedroff J, Aquilonius SM, Hartvig P, Bredberg E, Bjurling P, Langstrom B. Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson’s disease measured by positron emission tomography. Relations to motor response. Acta Neurol Scand. 1992;85:95–102.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Coelho M, Abreu D, Guedes LC, Rosa MM, Costa N, et al. Do patients with late-stage Parkinson’s disease still respond to levodopa? Parkinsonism Relat Disord. 2016;26:10–16.
   PubMed Web of Science ®Google Scholar
• Hadjiconstantinou M, Neff NH. Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson’s disease. CNS Neurosci Ther. 2008;14:340–51.
   PubMed Web of Science ®Google Scholar
• Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B. Levodopa-induced changes in synaptic dopamine in patients with Parkinson’s disease as measured by [11C]raclopride displacement and PET. Neurology. 1996;46:1430–6.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lennernas H, Gomes-Trolin C, Aquilonius SM. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson’s disease on individual drug combinations. Clin Neuropharmacol. 2002;25:89–96.
   PubMed Web of Science ®Google Scholar
• Bredberg E, Tedroff J, Aquilonius SM, Paalzow L. Pharmacokinetics and effects of levodopa in advanced Parkinson’s disease. Eur J Clin Pharmacol. 1990;39:385–9.
   PubMed Web of Science ®Google Scholar
• Bredberg E, Nilsson D, Johansson K, Aquilonius SM, Johnels B, Nystrom C, et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson’s disease. Eur J Clin Pharmacol. 1993;45:117–22.
   PubMed Web of Science ®Google Scholar
• Nilsson D, Hansson LE, Johansson K, Nystrom C, Paalzow L, Aquilonius SM. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol Scand. 1998;97:175–83.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol. 2008;31:63–73.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nystrom C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol. 2003;26:156–63.
   PubMed Web of Science ®Google Scholar
• Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease–long-term experience. Acta Neurol Scand. 2001;104:343–8.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64:216–23.
   PubMed Web of Science ®Google Scholar
• Busk K, Nyholm D. Long-term 24-h levodopa/carbidopa gel infusion in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:1000–1.
   PubMed Web of Science ®Google Scholar
• Nyholm D. Duodopa(R) treatment for advanced Parkinson’s disease: a review of efficacy and safety. Parkinsonism Relat Disord. 2012;18:916–29.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30:510–16.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141–9.
   PubMed Web of Science ®Google Scholar
• Antonini A, Odin P, Opiano L, Tomantschger V, Pacchetti C, Pickut B, et al. Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm (Vienna). 2013;120:1553–8.
   PubMed Web of Science ®Google Scholar
• Lang AE, Rodriguez RL, Boyd JT, Chouinard S, Zadikoff C, Espay AJ, et al. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016;31:538–46.
   PubMed Web of Science ®Google Scholar
• Politis M, Sauerbier A, Loane C, Pavese N, Martin A, Corcoran B, et al. Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson’s disease patients. Mov Disord. 2016 Nov 17. [Epub ahead of print].
   Web of Science ®Google Scholar
• Nyholm D, Stepien V. Levodopa fractionation in Parkinson’s disease. J Parkinsons Dis. 2014;4:89–96.
   PubMedGoogle Scholar
• Bibbiani F, Costantini LC, Patel R, Chase TN. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol. 2005;192:73–8.
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson’s disease. Eur J Clin Pharmacol. 1991;41:463–6.
   PubMed Web of Science ®Google Scholar
• Kuoppamaki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol. 2009;65:443–55.
   PubMed Web of Science ®Google Scholar
• Metman LV, Hoff J, Mouradian MM, Chase TN. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord. 1994;9:463–5.
   PubMed Web of Science ®Google Scholar
• Bredenberg S, Nyholm D, Aquilonius SM, Nystrom C. An automatic dose dispenser for microtablets–a new concept for individual dosage of drugs in tablet form. Int J Pharm. 2003;261:137–46.
   PubMed Web of Science ®Google Scholar
• van Riet-Nales DA, Hussain N, Sundberg KA, Eggenschwyler D, Ferris C, Robert JL, et al. Regulatory incentives to ensure better medicines for older people: From ICH E7 to the EMA reflection paper on quality aspects. Int J Pharm. 2016;512:343–51.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lewander T, Gomes-Trolin C, Backstrom T, Panagiotidis G, Ehrnebo M, et al. Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers. Clin Neuropharmacol. 2012;35:111–17.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Ehrnebo M, Lewander T, Trolin CG, Backstrom T, Panagiotidis G, et al. Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. Acta Neurol Scand. 2013;127:124–32.
   PubMed Web of Science ®Google Scholar
• Senek M, Aquilonius SM, Askmark H, Bergquist F, Constantinescu R, Ericsson A, et al. Levodopa/carbidopa microtablets in Parkinson’s disease: a study of pharmacokinetics and blinded motor assessment. Eur J Clin Pharmacol. 2017 Jan 18. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21:1133–44.
   PubMed Web of Science ®Google Scholar
• Wirdefeldt K, Odin P, Nyholm D. Levodopa-carbidopa intestinal gel in patients with Parkinson’s disease: a systematic review. CNS Drugs. 2016;30:381–404.
   PubMed Web of Science ®Google Scholar
• Virhammar J, Nyholm D. Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence and experience. Ther Adv Neurol Disord. 2017; in press.
   PubMed Web of Science ®Google Scholar
• Nyman R, Lundgren D, Nyholm D. Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease. J Vasc Interv Radiol. 2009;20:500–5.
   PubMed Web of Science ®Google Scholar
• Meppelink AM, Nyman R, van Laar T, Drent M, Prins T, Leenders KL. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson’s disease. Mov Disord. 2011;26:331–4.
   PubMed Web of Science ®Google Scholar
• van Laar T, Nyholm D, Nyman R. Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson’s disease. Acta Neurol Scand. 2016;133:208–15.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Kowalski J, Aquilonius SM. Wireless real-time electronic data capture for self-assessment of motor function and quality of life in Parkinson’s disease. Mov Disord. 2004;19:446–51.
   PubMed Web of Science ®Google Scholar
• Memedi M, Khan T, Grenholm P, Nyholm D, Westin J. Automatic and objective assessment of alternating tapping performance in Parkinson’s disease. Sensors (Basel). 2013;13:16965–84.
   PubMed Web of Science ®Google Scholar
• LeWitt PA. New levodopa therapeutic strategies. Parkinsonism Relat Disord. 2016;22(Suppl1):S37–S40.
   Web of Science ®Google Scholar
• Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease: a randomized crossover study. Mov Disord. 2016 Dec 17. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar